JPWO2020128527A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020128527A5 JPWO2020128527A5 JP2021536064A JP2021536064A JPWO2020128527A5 JP WO2020128527 A5 JPWO2020128527 A5 JP WO2020128527A5 JP 2021536064 A JP2021536064 A JP 2021536064A JP 2021536064 A JP2021536064 A JP 2021536064A JP WO2020128527 A5 JPWO2020128527 A5 JP WO2020128527A5
- Authority
- JP
- Japan
- Prior art keywords
- referred
- seq
- peptide ligand
- ligand according
- sar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 239000003446 ligand Substances 0.000 description 21
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002062 molecular scaffold Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- GHITVUOBZBZMND-UHFFFAOYSA-N 1,3,5-tris(bromomethyl)benzene Chemical compound BrCC1=CC(CBr)=CC(CBr)=C1 GHITVUOBZBZMND-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820969.2A GB201820969D0 (en) | 2018-12-21 | 2018-12-21 | Bicyclic peptide ligands specific for pd-l |
| GB1820969.2 | 2018-12-21 | ||
| GBGB1904622.6A GB201904622D0 (en) | 2019-04-02 | 2019-04-02 | Bicyclic peptide ligands specific for pd-l1 |
| GB1904622.6 | 2019-04-02 | ||
| PCT/GB2019/053680 WO2020128527A1 (en) | 2018-12-21 | 2019-12-23 | Bicyclic peptide ligands specific for pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514687A JP2022514687A (ja) | 2022-02-14 |
| JPWO2020128527A5 true JPWO2020128527A5 (enExample) | 2022-12-28 |
| JP7658902B2 JP7658902B2 (ja) | 2025-04-08 |
Family
ID=69104802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536064A Active JP7658902B2 (ja) | 2018-12-21 | 2019-12-23 | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220088207A1 (enExample) |
| EP (1) | EP3897850A1 (enExample) |
| JP (1) | JP7658902B2 (enExample) |
| CN (1) | CN113260420A (enExample) |
| WO (1) | WO2020128527A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017008575B1 (pt) | 2014-10-29 | 2021-07-13 | Bicyclerd Limited | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2022206577A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| WO2024261490A1 (en) | 2023-06-23 | 2024-12-26 | Bicycletx Limited | Bicyclic peptide ligands specific for nk cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| JP5372380B2 (ja) | 2005-01-24 | 2013-12-18 | ペプスキャン システムズ ベー．フェー． | 結合化合物、免疫原性化合物およびペプチド模倣体 |
| ES2509959T5 (en) | 2008-02-05 | 2024-12-19 | Bicyclerd Ltd | Methods and compositions |
| BR112017008575B1 (pt) | 2014-10-29 | 2021-07-13 | Bicyclerd Limited | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica |
| GB201607827D0 (en) * | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| JP7252526B2 (ja) * | 2017-01-23 | 2023-04-05 | スチョー アルファマブ カンパニー リミテッド | Ｐｄ－ｌ１結合ポリペプチド又は化合物 |
| GB2562721A (en) * | 2017-05-16 | 2018-11-28 | Fastbase Solutions Ltd | Kits, methods and their uses for detecting cell-cell interactions in a sample |
| SG11202009773VA (en) * | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
-
2019
- 2019-12-23 CN CN201980083299.2A patent/CN113260420A/zh active Pending
- 2019-12-23 JP JP2021536064A patent/JP7658902B2/ja active Active
- 2019-12-23 WO PCT/GB2019/053680 patent/WO2020128527A1/en not_active Ceased
- 2019-12-23 EP EP19831859.4A patent/EP3897850A1/en active Pending
- 2019-12-23 US US17/416,562 patent/US20220088207A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6223377B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| TWI362392B (en) | Acylated glp-1 compounds | |
| KR102627405B1 (ko) | 조절 방출 pth 화합물을 위한 투여 용법 | |
| AU2017336250B2 (en) | Incremental dose finding in controlled-release PTH compounds | |
| JPWO2020128527A5 (enExample) | ||
| JPWO2021019243A5 (enExample) | ||
| KR20230170810A (ko) | 낮은 피크 대 트로프 비를 가진 pth 화합물 | |
| JPWO2020148526A5 (enExample) | ||
| JPWO2021019244A5 (enExample) | ||
| JPWO2020148525A5 (enExample) | ||
| TW201811817A (zh) | 血小板反應素１結合肽 | |
| JPWO2020128526A5 (enExample) | ||
| JPWO2020120980A5 (enExample) | ||
| JPWO2020120981A5 (enExample) | ||
| JPWO2020148528A5 (enExample) | ||
| JPWO2020225577A5 (enExample) | ||
| JPWO2020148529A5 (enExample) | ||
| JPWO2020120983A5 (enExample) | ||
| JPWO2020148530A5 (enExample) | ||
| JP4563806B2 (ja) | Ｐ−セレクチンに対する結合性化合物 | |
| JPWO2020148527A5 (enExample) | ||
| JPWO2020120984A5 (enExample) | ||
| JP6046060B2 (ja) | エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 | |
| JPWO2020120979A5 (enExample) | ||
| HUP0401728A2 (hu) | P-szelektinhez szelektíven kötődő peptidszerű vegyületek |